Showing 5581-5590 of 9401 results for "".
- Psoriasis Therapy Linked to Reduced Coronary Inflammationhttps://practicaldermatology.com/news/psoriasis-therapy-linked-to-reduced-coronary-inflammation/2460112/Anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat a
- New AAD, NPF Guidelines Address Psoriasis Phototherapyhttps://practicaldermatology.com/news/new-aad-npf-guidelines-address-psoriasis-phototherapy/2460109/New guidelines from the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) take on psoriasis phototherapy. The
- PE-Backed Ownership of Dermatology Practices Is On The Risehttps://practicaldermatology.com/news/pe-backed-ownership-of-dermatology-practices-is-on-the-rise/2460104/Private equity firms have increased their financial stakes in dermatology practices throughout the United States, but exactly how this affects care is not fully understood yet. Private equity-backed dermatology management groups acquired 184 dermatology practices from 2012 to 2018, with
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 S
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- Second US Patent Issued to Alastin Based On TriHex Technologyhttps://practicaldermatology.com/news/second-us-patent-issued-to-alastin-based-on-trihex-technology/2460092/Alastin Skincare, Inc. was issued a second U.S. Patent, No. 10,286,030 from the United States Patent and Trademark Office covering Alastin's platform TriHex Technology. The patent also covers a variety of topical compositions based on Alastin's TriHex Technology. The coma
- Topical Collagen Powder May Be Effective for Wound Closurehttps://practicaldermatology.com/news/collagen-may-be-effective-for-wound-closure/2460091/Collagen powder is as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study published in the Journal of Drugs in Dermatology. Researchers investigated the efficacy of topical collagen powder compared
- Study Highlights Need for Tailored Skin Cancer Prevention Strategieshttps://practicaldermatology.com/news/study-highlights-need-for-tailored-skin-cancer-prevention-strategies/2460090/Sun safety practices for attendees at skin cancer screening events differ from the general public, according to findings published by researchers from the George Washington University (GW) Cancer Center. The study appears in the
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin
- Positive Results Seen in Phase 3 FMX101 Acne Studyhttps://practicaldermatology.com/news/study-positive-results-see-in-phase-3-fmx101-acne-study/2460088/In patients with moderate to severe acne vulgaris, treatment with FMX101 4% topical minocycline foam is well tolerated and effective for reducing the number of inflammatory lesions, according to results of a randomized trial published in the Journal of the American Academy of Dermatology